Pharmaceutical Industry Information Portal


All posts by tag


New investments in the innovative biotechnology company “Target Medicals”

RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant arterial hypertension. The Russian Direct Investment...

Russia approves AstraZeneca’s drug for coronavirus prophylaxis

The Russian Ministry of Health approved circulation of Evusheld, a COVID-19 prophylaxis drug by AstraZeneca, on the territory of the country, according to the...

AstraZeneca and Neurimmune sign exclusive global collaboration to develop and commercialise NI006

Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal...

The combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth

R-Pharm Group, the Russian Direct Investment Fund (RDIF) and AstraZeneca announce preliminary virus neutralizing activity results of combined use of the AstraZeneca vaccine (developed...

A combination between AstraZeneca and Sputnik Light demonstrates high immunogenicity profile

Clinical trials in Azerbaijan began in February 2021. To date 64 volunteers have been vaccinated, the enrollment of volunteers is ongoing.

Combination of the Sputnik Light with others vaccines demonstrates high safety profile

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

Expert Articles